ARCTArcturus Therapeutics Holdings Inc.
Price
-49%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
Quality shaky, a flag to check, growth fading, the market with it.
Charts
As reported to the SEC, without any scoring.
Arcturus Therapeutics Holdings Inc. (ARCT) reported revenue of $3.0M in Q2 2026 (quarter ended Jun 30, 2026), down 90% from the same quarter a year earlier. That came with net loss of $24M. For the full year FY2025, revenue was $82M (−46% year on year) and net income −$66M. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress.Earnings release · press release
- Jul 2, 2026On June 26, 2026, Arcturus Therapeutics, Inc. (“Arcturus”), a wholly-owned subsidiary of Arcturus Therapeutics Holdings Inc., a Delaware corporation (the “Company”), entered into a series of agreements with Thermo Fisher Scientific Inc. (“Thermo Fisher”) and certain of Thermo Fisher’s affiliates to establish a …Material agreement entered · Form 8-K
- May 7, 2026Effective May 1, 2026, Dennis Mulroy, 71, was appointed Chief Financial Officer of the Company. Mr. Mulroy will become the Company’s principal financial officer on the date immediately following the date on which the Company files its Quarterly Report on Form 10-Q for the period ended March 31, 2026.Earnings release · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.